EIF backs German-US life science fu

The European Investment Fund (EIF) has signed a cornerstone commitment in NGN BioMed Opportunity I GmbH and Co Beteiligungs KG, a joint German-US venture capital fund focusing on investments in development stage life science companies. The fund is to be managed by NGN Capital, a team consisting of four partners with offices in Heidelberg and New York. The team will carry out investments in both European countries (50%) - mainly Germany and German-speaking countries - and the US (50%).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH